Novel oral anticoagulants demonstrated a favorable safety profile with a 1.7% mortality rate, even though 63.3% of patients had a high bleeding risk (HAS-BLED score ≥3).
Does NOAC therapy improve clinical outcomes and maintain safety in real-world patients requiring anticoagulation?
Real-world use of NOACs in a tertiary care setting demonstrated a favorable safety profile with a low mortality rate of 1.7%, despite a high proportion of patients having a high risk for major bleeding (HAS-BLED score ≥3).
Tasa de eventos absoluta: 0% vs 0%
Introduction: Anticoagulants are highly effective in preventing thromboembolic events but are often used cautiously in clinical practice, sometimes leading to undertreatment despite a lower burden of certain risk factors. In this context, assessing the safety and clinical outcomes of NOAC therapy using real-world data, alongside clinical trials is essential to support informed clinical decision-making. Materials and Methods: This is a prospective and Retrospective (Ambispective) observational cohort study conducted over a period of six months in a tertiary care hospital setting. Data collection was performed using the electronic medical record system. All the data collected were analyzed based on the standard protocol. Results: The safety and clinical outcome parameters include mortality rate, which was found to be 1.7%, liver dysfunction which was seen 28.3% of patients and renal dysfunction which was seen in 24.16% all points toward a favorable safety profile of NOACs. HAS BLED Score, which assesses the risk for major bleeding was found to have been 0-1 in 18.3% patients 2 in 18.3% patients and 3or >3 in 63.3% patients. Conclusion: This study found that, in a real-world population of patients requiring NOAC therapy, treatment was associated with a favorable safety profile and excellent clinical outcomes. Conducted as both a prospective and retrospective observational study in a tertiary care hospital in Kannur, Kerala, it highlights the long-term performance of these medications in real-life clinical settings.
S. et al. (Mon,) reported a other. Novel oral anticoagulants demonstrated a favorable safety profile with a 1.7% mortality rate, even though 63.3% of patients had a high bleeding risk (HAS-BLED score ≥3).